Choosing a First-Line Combination Treatment Regimen for Renal Cell Carcinoma

Video

Drs Rana McKay and Tom Powles debate the merits of different first-line combination treatment regimens for renal cell carcinoma.

Thomas Powles, MBBS, MRCP, MD: The question I’m always asked on these podcasts or videos is which treatment do you use? Which do you select? Why?

Rana McKay, MD: Good question. It varies. We chatted a lot about I/O [immuno-oncology]–TKI [tyrosine kinase inhibitor] combinations. There are also I/O–I/O combos. We have over 5 years of follow-up data from the nivolumab-ipilimumab data, which show durability of response. The tail on the curve is hanging around 30% and continues to be consistent. There are 2 strategies. Do you need to play the short game, or do you need to play the long game? As I’m counseling patients about that, and as we think about choices in the clinic with nivolumab-ipilimumab, we’re largely playing the long game. Not that I want to compare, but the durability of that regimen is incredibly attractive.

But some individuals need to play the short game because they won’t have a long game. Patients who have an almost visceral crisis need to have a response. That’s where an I/O–VEGF comes in nicely. As we think about the nivolumab-ipilimumab data, while you have that 30% tail, about 1 of 5, 18%, are going to have primary PD. We don’t know who they are. We don’t know how to identify who those individuals are to not give them nivolumab-ipilimumab. These are questions that are in the field, but that’s how I try to strategize around it.

Lenvatinib-pembrolizumab is highly effective. I like to use that regimen in patients who have potentially locally advanced unresectable disease. I want an immediate short-term response to get them resected. That’s the perfect population because the response rate is so high and the primary PD rate is so low. That’s where I like to use this regimen.

Thomas Powles, MBBS, MRCP, MD: My thoughts are similar. For centers that are treating a handful of patients each year, rather than dozens of patients, it’s probably easier to pick 1 regimen and stick with it. I agree that nivolumab-ipilimumab is not for all patients. If you’re going to pick 1 regimen, it’s probably easier to use a VEGF TKI–I/O. There are some patients I’d give nivolumab-ipilimumab to. For example, patients with intermediate-risk disease and perhaps low-volume metastases, where I wouldn’t be worried if they got primary progression of disease. Those patients would be good candidates for nivolumab-ipilimumab.

We’ve talked about the good-risk patient. We know they can’t have nivolumab-ipilimumab; it’s not licensed. It’s a bit nuanced. But there’s nothing wrong with using VEGF TKI–I/O in unselected patients. All 3 regimens have attractive features. Pembrolizumab has a 0.53 hazard ratio, which came out first. People like axitinib; it has a short half-life. The lenvatinib-pembrolizumab data efficacy data look unbeatable from a PFS [progression-free survival] and response perspective. Everyone likes cabozantinib. Everyone likes nivolumab. Of course, the cabozantinib dose at 40 mg is attractive, and there are some good quality-of-life data as well. So you could make an argument for any of the 3 regimens. Picking 1 and using it well makes sense to me.

Rana McKay, MD: I completely agree with you. The dose modifications around the TKIs can get challenging. Having a strategy and a game plan is key to optimizing use for a clinician.

Transcript edited for clarity.

Recent Videos
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Related Content
Adverse reactions in the phase 3 ENVISION trial were largely mild to moderate in severity, and serious reactions occurred in 12% of those with NMIBC.

Mitomycin Exhibits Durable Responses in Recurrent, Low-Grade NMIBC

Roman Fabbricatore
August 7th 2025
Article

Adverse reactions in the phase 3 ENVISION trial were largely mild to moderate in severity, and serious reactions occurred in 12% of those with NMIBC.

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
July 28th 2025
Podcast

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Belzutifan Shows Superior Quality-Adjusted Survival in Advanced RCC

Belzutifan Shows Superior Quality-Adjusted Survival in Advanced RCC

Ariana Pelosci
July 30th 2025
Article

Data from the LITESPARK-005 Q-TWiST analysis show belzutifan’s improved quality-adjusted survival time and favorable toxicity profile vs everolimus in RCC.

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS
July 3rd 2025
Podcast

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.

Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.

Research Consortium Aims to Accelerate Progress in Kidney Cancer Management

Russ Conroy
July 25th 2025
Article

Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.

A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.

Analyzing Natural Killer Cell Restoration/KIM-1 Biomarker in Kidney Cancer

Roman Fabbricatore
July 24th 2025
Article

A genitourinary oncologist explained that KIM-1 can be used to diagnose, risk-stratify, and detect disease and monitor disease treatment in patients with kidney cancers.